Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

120.67
-3.6800-2.96%
Pre-market: 120.35-0.3200-0.27%06:06 EST
Volume:6.72M
Turnover:817.88M
Market Cap:149.71B
PE:18.79
High:125.11
Open:124.08
Low:119.93
Close:124.35
52wk High:128.70
52wk Low:88.57
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.25
T/O Rate:0.54%
Dividend:3.14
Dividend Rate:2.60%
EPS(TTM):6.42
EPS(LYR):0.3849
ROE:40.71%
ROA:12.57%
PB:6.95
PE(LYR):313.49

Loading ...

Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
14 hours ago

Gilead voluntarily recalls one lot of Veklury for Injection 100 mg/vial

TIPRANKS
·
19 hours ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $115 From $110, Maintains Neutral Rating

MT Newswires Live
·
19 hours ago

Gilead : RBC Cuts Target Price to $100 From $105

THOMSON REUTERS
·
Yesterday

UBS Upgrades Gilead Sciences to Buy From Neutral, Adjusts Price Target to $145 From $112

MT Newswires Live
·
Jan 07

Gilead Sciences Coverage Assumed by UBS at Buy vs Previous Rating of Neutral

Dow Jones
·
Jan 07

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin

Reuters
·
Jan 06

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Reuters
·
Jan 06

BUZZ-Citi sees momentum in US pharma and biotech into 2026, updates ratings on top picks

Reuters
·
Jan 06

Onconano Medicine Announces Research Collaboration With Gilead to Apply on-Board™ Delivery Technology to Gilead’s Drug Candidate

THOMSON REUTERS
·
Jan 06

Onconano Medicine: Gilead Has Option to Expand Deal by Nominating Additional Target for on-Board Technology, in Which Co Would Receive up to $300 Mln

THOMSON REUTERS
·
Jan 06

Gilead Sciences Partners with OncoNano Medicine to Develop Tumor-Targeted Drug Delivery

Reuters
·
Jan 06

Heard on the Street: Big Pharma Has More Going for It Than Obesity Drugs -- WSJ

Dow Jones
·
Jan 06

Biotech and Pharma Stocks Tumble as Investors Race into Energy -- Barrons.com

Dow Jones
·
Jan 06

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Dec 31, 2025

Gilead Sciences CEO Daniel O’Day Reports Sale of Common Shares

Reuters
·
Dec 31, 2025

U.S. Stock Movement | Repare Therapeutics (RPTX.US) Surges ~20% Pre-Market After Signing Deal with Gilead Sciences (GILD.US) for Experimental Cancer Asset

Stock News
·
Dec 24, 2025

Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment

MT Newswires Live
·
Dec 24, 2025

BRIEF-Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration

Reuters
·
Dec 24, 2025